US
CA
NZ
UK
AU
IND
Last update at 2025-06-16T15:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
3 Mid-Cap Stocks with Questionable Fundamentals
Thu 15 May 25, 04:35 AMUnderstanding Hologic (HOLX) Reliance on International Revenue
Tue 13 May 25, 01:16 PMTariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
Mon 12 May 25, 12:44 PMHologic's (NASDAQ:HOLX) Solid Earnings Are Supported By Other Strong Factors
Fri 09 May 25, 12:11 PM1 of Wall Street’s Favorite Stock with Impressive Fundamentals and 2 to Think Twice About
Tue 06 May 25, 04:32 AMHologic Second Quarter 2025 Earnings: EPS Misses Expectations
Sat 03 May 25, 02:35 PMQ2 2025 Hologic Inc Earnings Call
Fri 02 May 25, 02:11 PMHologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down
Fri 02 May 25, 11:25 AMHologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Thu 01 May 25, 09:30 PM| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Income before tax | 676.10M | 1588.20M | 2361.10M | 1001.90M | -95.30000M |
| Minority interest | - | 0.00000M | 1.80M | -4.70000M | 2.10M |
| Net income | 456.00M | 1302.00M | 1871.50M | 1115.20M | -40.20000M |
| Selling general administrative | 392.40M | 407.70M | 433.20M | 356.00M | 332.30M |
| Selling and marketing expenses | 595.20M | 630.30M | 561.20M | 484.60M | 564.90M |
| Gross profit | 2071.50M | 2997.40M | 3795.80M | 2227.50M | 1308.10M |
| Reconciled depreciation | 323.40M | 430.10M | 406.90M | 376.00M | 463.10M |
| Ebit | 880.30M | 1640.20M | 2480.30M | 1105.00M | 134.40M |
| Ebitda | 1203.70M | 2104.70M | 2885.80M | 1514.10M | 597.50M |
| Depreciation and amortization | 323.40M | 464.50M | 405.50M | 409.10M | 463.10M |
| Non operating income net other | - | 43.10M | -25.60000M | 13.40M | - |
| Operating income | 668.40M | 1640.20M | 2480.30M | 1105.00M | 134.40M |
| Other operating expenses | 3268.90M | 3232.00M | 3149.40M | 2651.70M | 3240.60M |
| Interest expense | 111.10M | 95.10M | 93.60M | 116.50M | 140.80M |
| Tax provision | 220.10M | 286.20M | 491.40M | -108.60000M | -54.10000M |
| Interest income | 120.50M | 12.90M | 1.40M | 4.30M | 4.60M |
| Net interest income | 9.40M | -82.20000M | -92.20000M | -112.20000M | -136.20000M |
| Extraordinary items | - | - | - | - | -5.00000M |
| Non recurring | - | 30.10M | 9.30M | 19.70M | - |
| Other items | - | - | - | - | - |
| Income tax expense | 220.10M | 286.20M | 491.40M | -108.60000M | -55.10000M |
| Total revenue | 4030.40M | 4862.80M | 5632.30M | 3776.40M | 3367.30M |
| Total operating expenses | 1310.00M | 1366.60M | 1312.90M | 1102.80M | 1181.40M |
| Cost of revenue | 1958.90M | 1865.40M | 1836.50M | 1548.90M | 2059.20M |
| Total other income expense net | -94.80000M | -52.00000M | -119.20000M | -103.10000M | -229.70000M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | 456.00M | 1302.00M | 1869.70M | 1110.50M | -203.60000M |
| Net income applicable to common shares | - | 1302.00M | 1871.50M | 1115.20M | -203.60000M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Total assets | 9139.30M | 9071.20M | 8919.90M | 7195.80M | 6611.10M |
| Intangible assets | 888.60M | 1280.60M | 1659.20M | 1307.50M | 1459.80M |
| Earning assets | - | - | - | - | - |
| Other current assets | 206.90M | 281.20M | 554.50M | 97.30M | 97.20M |
| Total liab | 4122.40M | 4195.00M | 4701.30M | 4488.50M | 4332.00M |
| Total stockholder equity | 5016.90M | 4876.20M | 4218.60M | 2705.20M | 2279.10M |
| Deferred long term liab | - | 100.20M | 270.80M | 214.70M | - |
| Other current liab | 8.20M | 538.50M | 599.90M | 549.50M | 432.70M |
| Common stock | 3.00M | 3.00M | 3.00M | 2.90M | 2.90M |
| Capital stock | - | 3.00M | 3.00M | 2.90M | 2.90M |
| Retained earnings | 2056.30M | 1600.30M | 298.30M | -1573.20000M | -2688.70000M |
| Other liab | - | 448.90M | 662.30M | 429.30M | 419.80M |
| Good will | 3281.30M | 3236.50M | 3281.60M | 2657.90M | 2563.70M |
| Other assets | - | 210.50M | 245.70M | 424.50M | 95.80M |
| Cash | 2722.50M | 2339.50M | 1170.30M | 701.00M | 601.80M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 1207.30M | 937.70M | 1326.80M | 1239.30M | 1070.10M |
| Current deferred revenue | 199.20M | 186.50M | 198.00M | 186.10M | 179.50M |
| Net debt | 95.70M | 483.90M | 1854.90M | 2337.80M | 2453.20M |
| Short term debt | 287.00M | 15.00M | 313.00M | 324.90M | 271.40M |
| Short long term debt | 287.00M | 15.00M | 313.00M | 324.90M | 271.40M |
| Short long term debt total | 2818.20M | 2823.40M | 3025.20M | 3038.80M | 3055.00M |
| Other stockholder equity | 3105.20M | 3511.10M | 3976.40M | 4325.20M | 5007.20M |
| Property plant equipment | - | 481.60M | 564.70M | 491.50M | 470.90M |
| Total current assets | 4184.50M | 3862.00M | 3168.70M | 2222.30M | 1792.60M |
| Long term investments | - | 5.50M | 9.50M | 11.40M | 54.10M |
| Net tangible assets | - | 359.10M | -722.20000M | -1260.20000M | -1907.80000M |
| Short term investments | - | - | - | - | - |
| Net receivables | 625.60M | 617.60M | 942.70M | 1028.90M | 648.70M |
| Long term debt | 2531.20M | 2808.40M | 2712.20M | 2713.90M | 2783.60M |
| Inventory | 617.60M | 623.70M | 501.20M | 395.10M | 444.90M |
| Accounts payable | 712.90M | 197.70M | 215.90M | 178.80M | 186.50M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | 2.10M | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -147.60000M | -238.20000M | -59.10000M | -49.70000M | -42.30000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 3.00M | 3.00M | 2.90M | 2.90M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | 1600.30M | 298.30M | -1573.20000M | - |
| Treasury stock | - | -2531.50000M | -1989.40000M | -1579.60000M | -926.00000M |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 267.90M | 188.80M | 214.30M | 489.70M | 90.30M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 4954.80M | 5209.20M | 5751.20M | 4973.50M | 4818.50M |
| Capital lease obligations | - | 98.20M | 119.40M | 17.40M | 54.70M |
| Long term debt total | - | 2808.40M | 2712.20M | 2731.30M | 2802.80M |
| Breakdown | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-09-30 | 2022-09-30 | 2021-09-30 | 2020-09-30 | 2019-09-30 |
| Investments | -152.10000M | -206.30000M | -1329.60000M | -141.60000M | -280.70000M |
| Change to liabilities | -8.60000M | -26.70000M | 34.40M | 106.10M | 8.90M |
| Total cashflows from investing activities | -152.10000M | -206.30000M | -1329.60000M | -141.60000M | -280.70000M |
| Net borrowings | -19.00000M | -212.30000M | -113.40000M | -23.20000M | -257.70000M |
| Total cash from financing activities | -483.20000M | -756.00000M | -529.80000M | -659.90000M | -431.50000M |
| Change to operating activities | 9.40M | 368.50M | -61.20000M | -190.20000M | -22.50000M |
| Net income | 456.00M | 1302.00M | 1869.70M | 1110.50M | -40.20000M |
| Change in cash | 416.20M | 1169.20M | 469.30M | 99.20M | -64.90000M |
| Begin period cash flow | 2339.50M | 1170.30M | 701.00M | 601.80M | 666.70M |
| End period cash flow | 2755.70M | 2339.50M | 1170.30M | 701.00M | 601.80M |
| Total cash from operating activities | 1051.20M | 2125.70M | 2330.40M | 896.60M | 649.50M |
| Issuance of capital stock | - | - | - | - | - |
| Depreciation | 323.40M | 430.10M | 406.90M | 376.00M | 463.10M |
| Other cashflows from investing activities | 13.10M | 79.50M | -2.20000M | -43.30000M | -35.30000M |
| Dividends paid | - | - | 51.30M | 65.60M | 49.80M |
| Change to inventory | -4.90000M | -136.60000M | -84.10000M | -25.30000M | -63.00000M |
| Change to account receivables | -1.50000M | 272.30M | 110.90M | -427.10000M | -76.50000M |
| Sale purchase of stock | -474.80000M | -542.10000M | -409.70000M | -653.60000M | -200.10000M |
| Other cashflows from financing activities | -32.40000M | 1438.30M | 1249.60M | 791.20M | 2049.30M |
| Change to netincome | 260.00M | -60.60000M | 39.00M | 16.20M | 546.30M |
| Capital expenditures | 150.20M | 127.20M | 162.70M | 156.40M | 113.60M |
| Change receivables | - | 272.30M | 110.90M | -427.10000M | - |
| Cash flows other operating | - | 406.10M | -43.30000M | -259.80000M | - |
| Exchange rate changes | - | - | - | - | - |
| Cash and cash equivalents changes | - | 1163.40M | 471.00M | 95.10M | - |
| Change in working capital | 11.80M | 454.20M | 13.00M | -636.30000M | -161.30000M |
| Stock based compensation | 79.60M | 66.70M | 65.00M | 83.30M | 62.00M |
| Other non cash items | 289.50M | 38.90M | 45.90M | 57.50M | 557.60M |
| Free cash flow | 901.00M | 1998.50M | 2167.70M | 740.20M | 535.90M |
Sector: Healthcare Industry: Medical Instruments & Supplies
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| HOLX Hologic Inc |
0.41 0.63% | 65.16 | 38.01 | 19.12 | 4.57 | 3.90 | 4.74 | 17.68 |
| ISRG Intuitive Surgical Inc |
9.05 1.77% | 521.23 | 73.05 | 61.73 | 19.15 | 10.25 | 18.41 | 59.92 |
| ESLOY Essilor International SA |
1.76 1.27% | 140.71 | 35.39 | 24.81 | 3.63 | 2.20 | 4.00 | 16.25 |
| ESLOF EssilorLuxottica Société anonyme |
-10.5 3.65% | 277.25 | 35.71 | 25.13 | 3.62 | 2.23 | 4.00 | 16.25 |
| BDX Becton Dickinson and Company |
0.44 0.26% | 172.65 | 37.72 | 15.92 | 3.25 | 2.49 | 4.08 | 17.10 |
Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.
250 Campus Drive, Marlborough, MA, United States, 01752
| Name | Title | Year Born |
|---|---|---|
| Mr. Stephen P. MacMillan | Chairman, CEO & Pres | 1964 |
| Ms. Karleen M. Oberton | Chief Financial Officer | 1971 |
| Mr. John M. Griffin | Gen. Counsel | 1961 |
| Mr. Kevin R. Thornal | Group Pres of Global Diagnostic Solutions | 1974 |
| Mr. Paul Malenchini | Chief Information Officer | NA |
| Ryan M. Simon | VP of Investor Relations | NA |
| Ms. Elisabeth A. Hellmann | Sr. VP of Global HR & Corp. Communications | 1969 |
| Mr. Jan Verstreken | Group Pres of International | 1968 |
| Ms. Monica Aguirre Berthelot | VP & Chief of Staff | NA |
| Mr. Mike Kelly | Chief Supply Chain Officer and Corp. VP of Quality Assurance & Regulatory Affairs | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...